ABSTRACT
AIMS: Neuropeptide Y (NPY) is a potent vasoconstrictor released during sympathetic activation that may be involved in myocardial ischaemia. We examined the effect of a Y1 receptor antagonist on haemodynamic and ischaemic responses to exercise in patients with coronary artery disease. METHODS AND RESULTS: Eighty-two evaluable male patients were included in a randomized, double blind, two-way crossover study with a low dose (6.7 microg/kg/min; n=59)and a high dose (13.3 microg/kg/min; n=23) of the Y1 receptor antagonist AR-H040922 given as infusions for 2h or placebo. Myocardial ischaemia during a symptom-limited exercise test was monitored by conventional ST-segment analysis and heart rate (HR)-adjusted ST changes including the ST/HR slope and ST/HR recovery. Administration of the high dose AR-H040922 attenuated systolic blood pressure by 6-11 mmHg (p<0.05) during and after exercise without affecting HR. None of the two doses of AR-H040922 influenced any of the ischaemic parameters or duration of exercise, however. The maximal increase in NPY was higher during AR-H040922 (p<0.05) compared with placebo. CONCLUSIONS: Selective NPY Y1 receptor blockade attenuates the increase in blood pressure during exercise indicating a role for endogenous NPY in blood pressure regulation. Despite this effect, the Y1 receptor antagonist did not influence exercise-induced ischaemic parameters in patients with coronary artery disease.
Subject(s)
Amides/therapeutic use , Angina Pectoris/drug therapy , Receptors, Neuropeptide Y/antagonists & inhibitors , Adult , Aged , Amides/blood , Blood Pressure/drug effects , Chronic Disease , Cross-Over Studies , Double-Blind Method , Electrocardiography , Exercise Test , Heart Rate/drug effects , Humans , Male , Middle Aged , Receptors, Neuropeptide Y/bloodABSTRACT
BACKGROUND: Beta-blockade usually causes a slight reduction in exercise capacity among healthy subjects, while more variable results have been observed in chronic heart failure (CHF), probably related to patients studied, methods and agent used. The effect of metoprolol controlled release/extended release (CR/XL) on peak oxygen uptake (peak VO(2)) in this patient population has not previously been investigated. AIMS: We examined the effect of long-term treatment with the selective beta(1)-receptor blocker metoprolol CR/XL once daily on exercise capacity in patients with CHF. METHODS: Ninety-four patients (70 males and 24 females; mean age 63.6+/-10.6 years) with chronic symptomatic heart failure in New York Heart Association (NYHA) functional class II-IV, and with ejection fraction Subject(s)
Exercise Tolerance/drug effects
, Heart Failure/drug therapy
, Metoprolol/administration & dosage
, Aged
, Chronic Disease
, Confidence Intervals
, Delayed-Action Preparations
, Double-Blind Method
, Drug Administration Schedule
, Female
, Follow-Up Studies
, Heart Failure/physiopathology
, Heart Function Tests
, Hemodynamics/drug effects
, Humans
, Long-Term Care
, Male
, Middle Aged
, Oxygen Consumption/physiology
, Probability
, Reference Values
, Treatment Outcome